Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody
Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumbersome CAR-T therapy.
At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting antibody, which has been approved in combination with BMS’ Revlimid (lenalidomide) for adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified.
The indication also covers DLBCL arising from low grade lymphoma and patients not eligible for autologous stem cell transplant.
Monjuvi (tafasitamab) targets the CD-19, a protein on the surface of B-cells that is also targeted by Amgen’s bispecific antibody Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL), as well as two CAR-T therapies – Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta (axicabtagene ciloleucel) – that are already approved for DLBCL and other B-cell cancers.
Under the agreement with Morphosys the companies will co-market the drugs in the US, while Incyte has exclusive rights outside the US.
The deal with Morphosys could see Incyte pay up to $1.1 billion should certain targets be achieved.
Xencor, which developed the drug before licensing it to Morphosys in 2010, will receive a $25 million milestone payment and a royalty on worldwide net sales.
Before any rebates or discounts Monjuvi’s wholesale price will average $16,500 per month in the first year of therapy, followed by an average of $13,000 per month in subsequent years because of a decrease in the required number of doses per cycle.
At around $198,000 for the first year this is pricey but may work out as less expensive than CAR-Ts from Novartis and Gilead, depending on how long patients stay on treatment.
CAR-Ts cost $373,000 in adult DLBCL for a single shot of the cell therapy.
CAR-Ts can be highly effective but are made by harvesting a patient’s own cells and modifying them to fight cancer – a lengthy process that might not appeal to all patients.
There are also dangerous side-effects with CAR-Ts, where doctors often have to manage “cytokine storms” where the immune system goes into overdrive and begins to attack a patient’s own body.
The FDA approval of Monjuvi was based on data from the MorphoSys-sponsored phase 2 L-MIND study, an open label, multicentre, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL.
Results from the study showed an overall response rate of 55%, including a complete response rate of 37% and a partial response rate of 18%.
Warnings and precautions for Monjuvi included infusion-related reactions, serious or severe myelosuppression (including neutropenia (50%), thrombocytopenia (18%), and anemia (7%)), infections (73%) and embryo-foetal toxicity. Neutropenia led to treatment discontinuation in 3.7% of patients.
This accelerated approval may depend on further confirmatory data from larger trials.
Updated to include pricing information, and removing outdated response data
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.